No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

BACKGROUND: The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesquita, Bárbara, Veiga, Isabel, Pereira, Deolinda, Tavares, Ana, Pinto, Isabel M, Pinto, Carla, Teixeira, Manuel R, Castedo, Sérgio
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199587/
https://www.ncbi.nlm.nih.gov/pubmed/16095531
http://dx.doi.org/10.1186/1471-2407-5-101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199587/
https://www.ncbi.nlm.nih.gov/pubmed/16095531
http://dx.doi.org/10.1186/1471-2407-5-101

Ejemplares similares